Loading...
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés, G Saunders, Mark P Rivera, F Sobrero, A Benson, A Guillén Ponce, C Cascinu, S Van Cutsem, E Macpherson, I Strumberg, D
Argilés, G
Saunders, Mark P
Rivera, F
Sobrero, A
Benson, A
Guillén Ponce, C
Cascinu, S
Van Cutsem, E
Macpherson, I
Strumberg, D
Citations
Altmetric:
Abstract
The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed. This study investigated regorafenib plus modified FOLFOX (mFOLFOX6) as first-line treatment of metastatic CRC.
Description
Date
2015-03-24
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 761.26 KB
Keywords
Type
Article
Citation
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. 2015: Eur J Cancer